I
Irune Ruiz
Publications - 32
Citations - 1305
Irune Ruiz is an academic researcher. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 13, co-authored 26 publications receiving 1075 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale.
José M. Quintana,Angel Padierna,Cristóbal Esteban,Inmaculada Arostegui,Amaia Bilbao,Irune Ruiz +5 more
TL;DR: Assessment of the psychometric properties of the Spanish version of the Hospital Anxiety and Depression Scale (HADS) finds no significant differences between the English and the French versions.
Journal ArticleDOI
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool
Lorea Manterola,Elizabeth Guruceaga,Jaime Gállego Pérez-Larraya,Marisol Gonzalez-Huarriz,Patricia Jauregui,Sonia Tejada,Ricardo Díez-Valle,Victor Segura,Nicolás Samprón,Cristina Barrena,Irune Ruiz,Amaia Agirre,Angel Ayuso,Javier Rodríguez,Alvaro Gonzalez,Enric Xipell,Ander Matheu,Adolfo López de Munain,Teresa Tuñón,Idoya Zazpe,Jesus Garcia-Foncillas,Sophie Paris,Jean Yves Delattre,Marta M. Alonso +23 more
TL;DR: A small noncoding RNA signature in microvesicles isolated from GBM patient serum is uncovered that could be used as a fast and reliable differential diagnostic biomarker.
Journal ArticleDOI
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Laura Garros-Regulez,Paula Aldaz,Olatz Arrizabalaga,Veronica Moncho-Amor,Estefania Carrasco-Garcia,Lorea Manterola,Leire Moreno-Cugnon,Cristina Barrena,Jorge Villanua,Irune Ruiz,Steven M. Pollard,Robin Lovell-Badge,Nicolás Samprón,Idoia Garcia,Ander Matheu +14 more
TL;DR: SOX2-SOX9 is revealed as an oncogenic axis that regulates stem cell properties and chemoresistance and is provided evidence that a combination of rapamycin and temozolomide inhibits tumor growth in cells with high SOX2/SOX 9 levels.
Journal ArticleDOI
Targeting SOX2 as a Therapeutic Strategy in Glioblastoma
Laura Garros-Regulez,Idoia Garcia,Estefania Carrasco-Garcia,Aquilino Lantero,Paula Aldaz,Leire Moreno-Cugnon,Olatz Arrizabalaga,J. Undabeitia,Sergio Torres-Bayona,Jorge Villanua,Irune Ruiz,Larraitz Egaña,Nicolás Samprón,Ander Matheu +13 more
TL;DR: This review will summarize the current knowledge about SOX2 in glioblastoma and recapitulate several strategies that have recently been described targeting SOx2 in this malignancy.
Journal ArticleDOI
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
J.F. Martí-Massó,Javier Ruiz-Martínez,Maria J. Bolaño,Irune Ruiz,Ana Gorostidi,Fermin Moreno,Isidre Ferrer,Adolfo López de Munain +7 more
TL;DR: The neuropathological examination disclosed mild neuronal loss in the substantia nigra pars compacta without α‐synuclein, tau, LRRK2, or ubiquitin cytoplasmic inclusions in a patient with Parkinson's disease associated with Basque R1441G‐L RRK2/dardarin mutation.